Summary
In a group of ten hypertensive patients, the effects of methyldopa administration in two different formulations on serum prolactin (PRL) were studied. A single oral dose of normal release methyldopa significantly increased serum prolactin levels, peak concentrations occurring 3 to 6 h after drug administration. On the contrary, administration of sustained release methyldopa at the same dose was only followed by slight and not significant fluctuations in prolactin plasma levels. Both formulations produced a significant decrease of systolic and diastolic blood pressures, without significant differences between sustained and normal release methyldopa effects.
This is a preview of subscription content, log in via an institution to check access.
References
Alexander WD, Evans JI (1975) Side effects of methyldopa (Letter). Br Med J 2: 501
Arze RS, Ramos JM, Rashid HU, Kerr DNS (1981) Amenorrhoea, galactorrhoea, and hyperprolactinaemia induced by methyldopa. Br Med J 283: 194
Baitsch G, Elsasser J, Cocco G, Cornelli U (1985) Antihypertensive activity of a new formulation of methyldopa. Med Prax 6: 33–48
Bulpitt CJ, Dollery CT (1973) Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J 3: 485–490
Horwitz D, Pettinger WA, Orvis H, Thomas RE, Sjoerdsma A (1966) Effects of methyldopa in fifty hypertensive patients. Clin Pharmacol Ther 8: 224–234
Johnson P, Kitchin AH, Lowther CP, Turner RWD (1966) Treatment of hypertension with methyldopa. Br Med J 1: 133–137
Kirk RE (1968) Experiment design: procedures for the behavioural sciences. Brooks/Cole, Belmont
Kopin I (1968) False adrenergic transmitters. Ann Rev Pharmacol 8: 377–383
MacLeod RM (1976) Regulation of prolactin secretion. In: Martini L, Ganong WF (eds) Frontiers in neuroendocrinology. Raven, New York
MacLeod RM, Lehmeyer JE (1974) Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94: 1077–1085
Meites J (1967) Control of mammary growth and lactation. In: Martini L, Ganong WF (eds) Neuroendocrinology. Academic, New York
Newman RJ, Salerno HR (1974) Sexual dysfunction due to methyldopa (Letter). Br Med J 4: 106
Pettinger WA, Horwitz D, Sjoerdsma A (1963) Lactation due to methyldopa. Br Med J 1: 1460–1463
Steiner J, Cassar J, Mashiter K, Dawes I, Russell Fraser T, Breckenridge A (1976) Effects of methyldopa on prolactin and growth hormone. Br Med J 1: 1186–1188
Turkington RW (1972) Prolactin secretion in patients treated with various drugs. Arch Intern Med 130: 349–354
Vaidya RA, Vaidya AB, Van Woert MH, Kase NG (1970) Galactorrhea and Parkinson-like syndrome: an adverse effect of a-methyldopa. Metabolism 19: 1068–1071
Wiggins JF, Sved AF, Fernstrom JD (1980) Effects of alpha-methyldopa and its metabolites on prolactin release: in vivo and in vitro studies. J Pharmacol Exp Ther 212: 304–308
Zavisca FG, Breau AP, Wurtman RJ (1979) Mechanism of action of methyldopa in the rat. Role of 3-0-methylated metabolites. Circ Res 45: 684–690
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baldini, M., Cornelli, U., Molinari, M. et al. Effect of methyldopa on prolactin serum concentration. Eur J Clin Pharmacol 34, 513–515 (1988). https://doi.org/10.1007/BF01046712
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01046712